55 Stocks Moving In Friday’s Mid-Day Session
Gainers
Swvl Holdings Corp. (NASDAQ: SWVL) surged 24.4% to $7.50. Swvl Holdings 13D Filing from investor Ahmed Sabbah showed a new 6.4% stake in the company.
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.
Jounce Therapeutics Q1 2022 Earnings Conference Call On May 5, 2022 At 08:00 AM ET
Jounce Therapeutics (NASDAQ:JNCE) will host a conference call at 08:00 AM ET on May 5, 2022, to discuss Q1 2022 earnings results.
Jounce Therapeutics Q4 EPS $(0.59) Misses $(0.32) Estimate
Jounce Therapeutics (NASDAQ:JNCE) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.32) by 84.37 percent. This is a 168.6 percent decrease over earnings of $0.86 per share
Earnings Scheduled For March 2, 2022
Companies Reporting Before The Bell
• SIGNA Sports United (NYSE:SSU) is expected to report quarterly loss at $0.04 per share on revenue of $283.61 million.
Earnings Outlook For Jounce Therapeutics
Jounce Therapeutics (NASDAQ:JNCE) is set to give its latest quarterly earnings report on Wednesday, 2022-03-02. Here's what investors need to know before the announcement.
Analysts estimate that Jounce Therapeutics will report an earnings per share (EPS) of $-0.32.
Cowen & Co. Upgrades Jounce Therapeutics to Outperform
Cowen & Co. analyst Boris Peaker upgrades Jounce Therapeutics (NASDAQ:JNCE) from Market Perform to Outperform.
Raymond James Maintains Outperform on Jounce Therapeutics, Raises Price Target to $15
Raymond James analyst Steven Seedhouse maintains Jounce Therapeutics (NASDAQ:JNCE) with a Outperform and raises the price target from $10 to $15.
Earnings Scheduled For November 4, 2021
Companies Reporting Before The Bell
• DISH Network (NASDAQ:DISH) is likely to report quarterly earnings at $0.91 per share on revenue of $4.45 billion.
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected.